Overview of DEFA10P: Potential Drug Target and Biomarker (G449493)

Target Name: DEFA10P

NCBI ID: G449493

DEFA10P

Other Name(s): defensin alpha 10, pseudogene | Defensin alpha 10, pseudogene

Overview of DEFA10P: Potential Drug Target and Biomarker

Defensin alpha-10 (DEFA10P) is a protein that is expressed in various cell types of the human body, including the immune system, skin, and hair. It is a member of the defensin family of proteins, which are involved in the regulation of immune responses and inflammation. While DEFA10P has been identified as a potential drug target and biomarker, its exact function and potential therapeutic applications are not yet fully understood.

Purpose of the Article

The purpose of this article is to provide an overview of DEFA10P, including its structure, function, and potential as a drug target and biomarker. This will include an examination of its biology, its potential clinical applications, and its potential as a drug target.

Structure and Function

DEFA10P is a 144 amino acid protein that is expressed in various cell types of the human body. It is a member of the defensin family of proteins, which are characterized by the presence of a conserved region known as the defensin signature. This signature is present in a variety of proteins, including DEFA10P, and is involved in the regulation of immune responses and inflammation.

One of the unique features of DEFA10P is its ability to interact with other proteins in the defensin family. This allows DEFA10P to play a role in the regulation of both cellular and systemic inflammation. In addition, DEFA10P has been shown to be involved in the regulation of cellular responses to infection, including the response of immune cells to viruses and bacteria.

DEFA10P has also been shown to play a role in the regulation of cell death, which is a critical aspect of both normal cellular function and the regulation of disease. In addition, DEFA10P has been shown to be involved in the regulation of cell growth, which is important for both the development and maintenance of tissues and organs.

Potential Clinical Applications

DEFA10P has the potential to be a drug target and biomarker in a variety of diseases. Its ability to interact with other proteins in the defensin family makes it a potential candidate for drugs that target the defensin signaling pathway. In addition, DEFA10P's involvement in the regulation of cellular responses to infection and inflammation makes it a potential candidate for drugs that are effective in treating bacterial and viral infections.

In addition to its potential as a drug, DEFA10P also has the potential to be a biomarker for a variety of diseases. Its ability to interact with other proteins in the defensin family makes it a potential candidate for use as a biomarker for a variety of diseases, including cancer, autoimmune diseases, and neurodegenerative diseases.

Conclusion

In conclusion, DEFA10P is a protein that has the potential to be a drug target and biomarker in a variety of diseases. Its ability to interact with other proteins in the defensin family and its involvement in the regulation of cellular responses to infection and inflammation make it a promising candidate for both drug and biomarker development. Further research is needed to fully understand its function and potential as a drug target and biomarker.

Protein Name: Defensin Alpha 10, Pseudogene

The "DEFA10P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFA10P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets